Group 1 - The core viewpoint of the article highlights the recent stock performance of Spring Medical, which has seen a year-to-date increase of 77.40%, but a decline of 4.84% over the last five trading days [2][3] - As of August 22, Spring Medical's stock price was reported at 22.62 yuan per share, with a market capitalization of 8.676 billion yuan [1] - The company primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - Spring Medical's revenue for the first quarter of 2025 reached 230 million yuan, reflecting a year-on-year growth of 3.60%, while the net profit attributable to shareholders was 58.071 million yuan, up 5.20% year-on-year [3] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4] - As of March 31, 2025, the number of shareholders increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [3]

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant stock performance, with an 88.85% increase in stock price year-to-date, despite a recent decline of 3.99% over the last five trading days [1] - As of August 19, the stock price of Spring Medical is 24.08 CNY per share, with a market capitalization of 9.236 billion CNY and a trading volume of 13.42 million CNY [1] - The company primarily engages in the research, production, and sales of orthopedic medical devices, focusing on joint prosthetics and spinal implants, with 99.92% of its revenue coming from medical device products [1][2] Group 2 - As of March 31, the company reported a revenue of 230 million CNY for Q1 2025, representing a year-on-year growth of 3.60%, and a net profit of 58.07 million CNY, which is a 5.20% increase compared to the previous year [2] - The company has distributed a total of 359 million CNY in dividends since its A-share listing, with 309 million CNY distributed over the past three years [3] - The number of shareholders increased by 7.48% to 7,182 as of March 31, while the average number of circulating shares per person decreased by 6.99% to 11,063 shares [2]

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][3][8]. Group 1: Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021 [7]. - The company's main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal implant products [8]. - The company has achieved a revenue composition of 99.92% from medical device products and 0.08% from other sources [8]. Group 2: Product Development and Innovation - The company has developed a range of orthopedic products, including hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2]. - Spring Medical is in the design and inspection phase for a customized porous tantalum dental implant product [2]. Group 3: Industry Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises [3]. Group 4: Financial Performance - For the period from January to March 2025, Spring Medical reported a revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.20% year-on-year [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [9]. Group 5: Market Activity - On August 13, the stock price of Spring Medical decreased by 0.04%, with a trading volume of 85.43 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 9.616 billion yuan [1]. - The stock has seen a net inflow of 669,900 yuan from major funds today, with a ranking of 29 out of 131 in its industry [4].

类别本次变动前（万股）本次变动数（万股）本次变动后（万股）有限售条件股份20913.3320913.330无 限售条件股份17443.5220913.3338356.85 此解禁股类型属于首发原股东限售股份，截止6月19日，公司收盘价（首发发行日后复权）为16.85元/ 股，首发发行价为29.81元/股，较发行价涨跌幅为-43.48%。 一般而言，在公司基本面较差或估值水平较高情况下，则需要关注高解禁股未来可能潜藏的减持风险。 具体公司而言： 春立医疗6月20日发布公告称，公司部分限售股即将解禁上市，本次解除限售股份的数量为2.09亿股， 占公司发行总股本的54.52%。本次解除限售的股份上市流通日期为2025年6月30日，解禁股类型为首 发。 此次解禁股东共2位，分别为史春宝、岳术俊，对应解禁股份分别为1.14亿、9544.79万。 股东名称是否为控股股东、实际控制人或其一致行动人董事、监事、高级管理人员任职情况解禁股类型 本次解除限售登记股票数量本次解除限售股数占公司总股本比例尚未解除限售的股票数量史春宝是执行 董事、核心技术人员、总工程师首发11368543529.64%0岳术俊是副总经理、执行董事首发 ...

Company Overview - Spring Medical is a Chinese company primarily engaged in the research, production, and sales of implantable orthopedic medical devices, established on February 12, 1998, and listed on December 30, 2021 [1] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [1] - The revenue composition of the company is 99.92% from medical device products and 0.08% from other sources [1] Stock Performance - On June 19, Spring Medical's stock price fell by 3.15%, closing at 15.97 yuan per share, with a trading volume of 27.87 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 6.126 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.06% during this period [1] Fund Holdings - According to data from major funds, Nord Fund has a significant holding in Spring Medical, with the Nord New Prosperity Fund (005293) holding 70,000 shares, accounting for 4.66% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 36,400 yuan today and a total floating loss of 72,100 yuan during the three-day decline [2] Fund Manager Information - The fund manager of Nord New Prosperity Fund is Zhu Mingrui, who has been in the position for 2 years and 352 days, managing a total asset size of 63.1 million yuan [3] - During his tenure, the best fund return was 12.93%, while the worst return was -21.39% [3]